Ursodeoxycholsav kezelés primer biliaris cirrhosisban.

Translated title of the contribution: Ursodeoxycholic acid therapy in biliary cirrhosis

L. Herszényi, L. Szalay, Z. Schaff, P. Gergely, J. Fehér

Research output: Contribution to journalArticle

Abstract

Six female patients (mean age 48.5 years) suffering from primary biliary cirrhosis were evaluated during ursodeoxycholic acid (UDCA, Ursofalk, 10 mg/kg/day) therapy. The following examinations were performed: liver function tests, immunological studies [electrophoresis, immunoglobulin determination, T-B lymphocyte rate, antibody dependent cellularly cytotoxicity (ADCC), natural killer (NK) activity, blast transformation]. The patients showed a definite clinical improvement. Short term therapy (1 month) resulted in a decrease of gamma-GT, SGPT (ALT), SGOT (AST), bilirubin, alkaline phosphatase, cholesterol, triglyceride. The longer period of therapy (9 month) was associated with decrement in transaminase and gamma-GT levels. The statistically significant decrease of the IgG level, NK activity and spontaneous blast transformation during therapy suggest a potential immunosuppressive effect of the UDCA treatment. The authors believe that the use of UDCA could be effective in the treatment of primary biliary cirrhosis.

Original languageHungarian
Pages (from-to)2085-2089
Number of pages5
JournalOrvosi Hetilap
Volume134
Issue number38
Publication statusPublished - Sep 19 1993

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Lymphocyte Activation
Therapeutics
Liver Function Tests
Immunosuppressive Agents
Aspartate Aminotransferases
Transaminases
Alanine Transaminase
Bilirubin
Alkaline Phosphatase
Electrophoresis
Immunoglobulins
Triglycerides
B-Lymphocytes
Immunoglobulin G
Cholesterol
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ursodeoxycholsav kezelés primer biliaris cirrhosisban. / Herszényi, L.; Szalay, L.; Schaff, Z.; Gergely, P.; Fehér, J.

In: Orvosi Hetilap, Vol. 134, No. 38, 19.09.1993, p. 2085-2089.

Research output: Contribution to journalArticle

Herszényi, L. ; Szalay, L. ; Schaff, Z. ; Gergely, P. ; Fehér, J. / Ursodeoxycholsav kezelés primer biliaris cirrhosisban. In: Orvosi Hetilap. 1993 ; Vol. 134, No. 38. pp. 2085-2089.
@article{32f2c4a92d40407d885c06d3092435b5,
title = "Ursodeoxycholsav kezel{\'e}s primer biliaris cirrhosisban.",
abstract = "Six female patients (mean age 48.5 years) suffering from primary biliary cirrhosis were evaluated during ursodeoxycholic acid (UDCA, Ursofalk, 10 mg/kg/day) therapy. The following examinations were performed: liver function tests, immunological studies [electrophoresis, immunoglobulin determination, T-B lymphocyte rate, antibody dependent cellularly cytotoxicity (ADCC), natural killer (NK) activity, blast transformation]. The patients showed a definite clinical improvement. Short term therapy (1 month) resulted in a decrease of gamma-GT, SGPT (ALT), SGOT (AST), bilirubin, alkaline phosphatase, cholesterol, triglyceride. The longer period of therapy (9 month) was associated with decrement in transaminase and gamma-GT levels. The statistically significant decrease of the IgG level, NK activity and spontaneous blast transformation during therapy suggest a potential immunosuppressive effect of the UDCA treatment. The authors believe that the use of UDCA could be effective in the treatment of primary biliary cirrhosis.",
author = "L. Hersz{\'e}nyi and L. Szalay and Z. Schaff and P. Gergely and J. Feh{\'e}r",
year = "1993",
month = "9",
day = "19",
language = "Hungarian",
volume = "134",
pages = "2085--2089",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "38",

}

TY - JOUR

T1 - Ursodeoxycholsav kezelés primer biliaris cirrhosisban.

AU - Herszényi, L.

AU - Szalay, L.

AU - Schaff, Z.

AU - Gergely, P.

AU - Fehér, J.

PY - 1993/9/19

Y1 - 1993/9/19

N2 - Six female patients (mean age 48.5 years) suffering from primary biliary cirrhosis were evaluated during ursodeoxycholic acid (UDCA, Ursofalk, 10 mg/kg/day) therapy. The following examinations were performed: liver function tests, immunological studies [electrophoresis, immunoglobulin determination, T-B lymphocyte rate, antibody dependent cellularly cytotoxicity (ADCC), natural killer (NK) activity, blast transformation]. The patients showed a definite clinical improvement. Short term therapy (1 month) resulted in a decrease of gamma-GT, SGPT (ALT), SGOT (AST), bilirubin, alkaline phosphatase, cholesterol, triglyceride. The longer period of therapy (9 month) was associated with decrement in transaminase and gamma-GT levels. The statistically significant decrease of the IgG level, NK activity and spontaneous blast transformation during therapy suggest a potential immunosuppressive effect of the UDCA treatment. The authors believe that the use of UDCA could be effective in the treatment of primary biliary cirrhosis.

AB - Six female patients (mean age 48.5 years) suffering from primary biliary cirrhosis were evaluated during ursodeoxycholic acid (UDCA, Ursofalk, 10 mg/kg/day) therapy. The following examinations were performed: liver function tests, immunological studies [electrophoresis, immunoglobulin determination, T-B lymphocyte rate, antibody dependent cellularly cytotoxicity (ADCC), natural killer (NK) activity, blast transformation]. The patients showed a definite clinical improvement. Short term therapy (1 month) resulted in a decrease of gamma-GT, SGPT (ALT), SGOT (AST), bilirubin, alkaline phosphatase, cholesterol, triglyceride. The longer period of therapy (9 month) was associated with decrement in transaminase and gamma-GT levels. The statistically significant decrease of the IgG level, NK activity and spontaneous blast transformation during therapy suggest a potential immunosuppressive effect of the UDCA treatment. The authors believe that the use of UDCA could be effective in the treatment of primary biliary cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=0027920485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027920485&partnerID=8YFLogxK

M3 - Article

C2 - 8414454

AN - SCOPUS:0027920485

VL - 134

SP - 2085

EP - 2089

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 38

ER -